Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01481051 · ClinicalTrials.gov registry record · Phase 2
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
A Phase 2 study of Glaucoma and Ocular Hypertension (OH), sponsored by Mati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 6
- Study locations
NCT01481051: Completed Phase 2 study of Glaucoma and Ocular Hypertension (OH), sponsored by Mati Therapeutics.
NCT01481051 is a Phase 2 study of Glaucoma and Ocular Hypertension (OH) that has completed, run by Mati Therapeutics. The registered enrollment target is 57 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01481051, a Phase 2 study of Glaucoma and Ocular Hypertension (OH), has completed, sponsored by Mati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.
Conditions Studied
Interventions
- DRUG Latanoprost-PPDS
Study Locations (6)
California
- Sall Research Medical Center, Inc - Artesia
- Wolstan & Goldberg Eye Associates - Los Angeles
- West Coast Eye Care Associates - San Diego
Georgia
- Coastal Research Associates, LLC - Roswell
Texas
- R and R Eye Associates - San Antonio
Utah
- Rocky Mountain Eye Care Associates - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01481051 record still lists
NCT01481051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Latanoprost-PPDS is the first listed.
NCT01481051 lists 6 locations in 4 states (California, Georgia, Texas).
Frequently Asked Questions
What is clinical trial NCT01481051 about?
NCT01481051 is a clinical study titled "A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma". The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.
What is the current status of trial NCT01481051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2011-11. Estimated completion is 2012-09.
What conditions does trial NCT01481051 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension (OH).
What interventions are being tested in trial NCT01481051?
The interventions under investigation include: Latanoprost-PPDS (DRUG).
Who is sponsoring clinical trial NCT01481051?
This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01481051 being conducted?
This trial has 6 study locations across California, Georgia, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01481051's enrollment target sits among peer trials
57 61st of 92 higher than 31 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia